Nuveen Asset Management LLC bought a new position in Cabot Corp (NYSE:CBT) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 228,190 shares of the specialty chemicals company’s stock, valued at approximately $10,887,000. Nuveen Asset Management LLC owned 0.39% of Cabot at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Jane Street Group LLC acquired a new stake in Cabot in the second quarter worth approximately $318,000. Morgan Stanley lifted its position in Cabot by 119.6% in the second quarter. Morgan Stanley now owns 50,950 shares of the specialty chemicals company’s stock worth $2,430,000 after purchasing an additional 27,747 shares during the period. Paloma Partners Management Co acquired a new stake in Cabot in the second quarter worth approximately $1,115,000. Bank of America Corp DE lifted its position in shares of Cabot by 17.6% during the 2nd quarter. Bank of America Corp DE now owns 1,196,424 shares of the specialty chemicals company’s stock valued at $57,082,000 after acquiring an additional 178,945 shares during the last quarter. Finally, Zebra Capital Management LLC lifted its position in shares of Cabot by 4.4% during the 2nd quarter. Zebra Capital Management LLC now owns 9,695 shares of the specialty chemicals company’s stock valued at $463,000 after acquiring an additional 409 shares during the last quarter. Hedge funds and other institutional investors own 85.83% of the company’s stock.
Shares of NYSE:CBT opened at $44.49 on Friday. Cabot Corp has a one year low of $37.11 and a one year high of $55.36. The stock has a fifty day moving average of $42.94 and a 200-day moving average of $43.89. The company has a market capitalization of $2.47 billion, a PE ratio of 11.06, a price-to-earnings-growth ratio of 0.99 and a beta of 1.51. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.27 and a current ratio of 2.07.
CBT has been the subject of a number of recent research reports. JPMorgan Chase & Co. cut their price objective on Cabot from $50.00 to $40.00 and set an “overweight” rating for the company in a research report on Tuesday, August 13th. Zacks Investment Research downgraded Cabot from a “hold” rating to a “sell” rating and set a $42.00 price objective for the company. in a research report on Friday, August 9th. Northcoast Research set a $45.00 price objective on Cabot and gave the company a “buy” rating in a research report on Wednesday, August 7th. ValuEngine upgraded Cabot from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, Loop Capital downgraded Cabot from a “buy” rating to a “hold” rating and cut their price objective for the company from $69.00 to $41.00 in a research report on Monday, August 5th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $42.60.
Cabot Corporation operates as a specialty chemicals and performance materials company. The company offers rubber grade carbon blacks used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and compounds of carbon black and rubber.
Want to see what other hedge funds are holding CBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cabot Corp (NYSE:CBT).
Receive News & Ratings for Cabot Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabot and related companies with MarketBeat.com's FREE daily email newsletter.